Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 237

1.

A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.

Tarhini AA, Millward M, Mainwaring P, Kefford R, Logan T, Pavlick A, Kathman SJ, Laubscher KH, Dar MM, Kirkwood JM.

Cancer. 2009 Feb 15;115(4):859-68. doi: 10.1002/cncr.24100.

PMID:
19140204
[PubMed - indexed for MEDLINE]
Free Article
2.

Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.

Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS.

J Clin Oncol. 2007 Sep 1;25(25):3802-7.

PMID:
17761969
[PubMed - indexed for MEDLINE]
Free Article
3.

Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.

Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB.

J Clin Oncol. 2003 Jul 1;21(13):2564-73.

PMID:
12829677
[PubMed - indexed for MEDLINE]
4.

Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.

García M, del Muro XG, Tres A, Crespo C, Valladares M, López JJ, Rifà J, Pérez X, Filipovich E, Germà-Lluch JR.

Melanoma Res. 2006 Aug;16(4):365-70.

PMID:
16845333
[PubMed - indexed for MEDLINE]
5.

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.

Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM.

J Clin Oncol. 2005 Sep 20;23(27):6747-55.

PMID:
16170182
[PubMed - indexed for MEDLINE]
Free Article
6.

Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.

Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, Pavlick AC.

Chemotherapy. 2009;55(4):221-7. doi: 10.1159/000219435. Epub 2009 May 19.

PMID:
19451711
[PubMed - indexed for MEDLINE]
7.

A phase II study of bortezomib in the treatment of metastatic malignant melanoma.

Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA, Erlichman C.

Cancer. 2005 Jun 15;103(12):2584-9.

PMID:
15887220
[PubMed - indexed for MEDLINE]
Free Article
8.

Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group.

Gogas H, Bafaloukos D, Aravantinos G, Fountzilas G, Tsoutsos D, Panagiotou P, Frangia K, Kalofonos HP, Briasoulis E, Castana O, Polyzos A, Pectasides D, Ioannovich J; Hellenic Cooperative Oncology Group.

Cancer Invest. 2004;22(6):832-9.

PMID:
15641480
[PubMed - indexed for MEDLINE]
9.

Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma.

Eton O, Talpaz M, Lee KH, Rothberg JM, Brell JM, Benjamin RS.

Cancer. 1996 Mar 1;77(5):893-9.

PMID:
8608480
[PubMed - indexed for MEDLINE]
10.

Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.

Hwu WJ, Panageas KS, Menell JH, Lamb LA, Aird S, Krown SE, Williams LJ, Chapman PB, Livingston PO, Wolchok JD, Houghton AN.

Cancer. 2006 Jun 1;106(11):2445-51.

PMID:
16639739
[PubMed - indexed for MEDLINE]
Free Article
11.

A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.

Laber DA, Okeke RI, Arce-Lara C, Taft BS, Schonard CL, McMasters KM, Kloecker GH, Miller DM.

J Cancer Res Clin Oncol. 2006 Sep;132(9):611-6. Epub 2006 Jun 2.

PMID:
16741726
[PubMed - indexed for MEDLINE]
12.

Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.

Weber RW, O'Day S, Rose M, Deck R, Ames P, Good J, Meyer J, Allen R, Trautvetter S, Timmerman M, Cruickshank S, Cook M, Gonzalez R, Spitler LE.

J Clin Oncol. 2005 Dec 10;23(35):8992-9000. Epub 2005 Oct 31.

PMID:
16260693
[PubMed - indexed for MEDLINE]
Free Article
13.

Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.

Hess V, Herrmann R, Veelken H, Schwabe M.

Oncology. 2007;73(1-2):33-40. doi: 10.1159/000120029. Epub 2008 Mar 10.

PMID:
18332650
[PubMed - indexed for MEDLINE]
14.

Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.

Masucci GV, Månsson-Brahme E, Ragnarsson-Olding B, Nilsson B, Wagenius G, Hansson J.

Melanoma Res. 2006 Aug;16(4):357-63.

PMID:
16845332
[PubMed - indexed for MEDLINE]
15.

Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.

Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB.

Clin Cancer Res. 2000 May;6(5):1678-92.

PMID:
10815886
[PubMed - indexed for MEDLINE]
Free Article
16.

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.

Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ.

Clin Cancer Res. 2009 Sep 1;15(17):5591-8. doi: 10.1158/1078-0432.CCR-09-1024. Epub 2009 Aug 11.

PMID:
19671877
[PubMed - indexed for MEDLINE]
Free Article
17.

Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.

Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ, Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN.

Cancer. 2005 Jun 15;103(12):2590-7.

PMID:
15861414
[PubMed - indexed for MEDLINE]
Free Article
18.

A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment.

Solti M, Berd D, Mastrangelo MJ, Sato T.

Melanoma Res. 2007 Aug;17(4):225-31.

PMID:
17625452
[PubMed - indexed for MEDLINE]
19.

A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma.

Safwat A, Schmidt H, Bastholt L, Fode K, Larsen S, Aggerholm N, von der Maase H.

Radiother Oncol. 2005 Nov;77(2):143-7. Epub 2005 Oct 10.

PMID:
16216360
[PubMed - indexed for MEDLINE]
20.

Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.

Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY.

Cancer. 2004 Aug 1;101(3):596-603.

PMID:
15274073
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk